Citations

Mayo Clinic

Showing 10 of 108523 citations.

Effects of anesthesia and surgery on the developing brain: problem solved?
Flick, Randall P., Warner, David O.

Pediatric Anesthesia | March 5, 2015 | Volume: 25 | Issue: 4 | Pages: 435-436

10.1111/pan.12624 | PMID 25752789 Get It

Cortisol Reactivity in Two-Year-Old Children Prenatally Exposed to Methamphetamine
Kirlić, Namik , Newman, Elana , LaGasse, Linda L. , Derauf, Chris, Shah, Rizwan, Smith, Lynne M. , Haning, William, Strauss, Arthur, DellaGrotta, Sheri A., Dansereau, Lynne M., Abar, Beau , Neal, Charles R., Lester, Barry M. , Arria, Amelia M. , Huestis, Marilyn Ann

Journal of Studies on Alcohol and Drugs | March 5, 2015 | Volume: 74 | Issue: 3 | Pages: 447-451

10.15288/jsad.2013.74.447 | PMID 23490574 Get It

Validity of the MacAndrew scale in a general medical population.
Davis, Leo J., Colligan, Robert C., Morse, R., Offord, Kenneth P.

Journal of Studies on Alcohol | March 5, 2015 | Volume: 48 | Issue: 3 | Pages: 202-206

10.15288/jsa.1987.48.202 | PMID 3657161 Get It

Treating the hearing-impaired in a standard chemical dependence unit.
Larson, E W, McAlpine, David

Journal of Studies on Alcohol | March 5, 2015 | Volume: 49 | Issue: 4 | Pages: 381-383

10.15288/jsa.1988.49.381 | PMID 3172789 Get It

Treating nondepressed smokers with alcohol dependence in sustained full remission: nicotine patch therapy tailored to baseline serum cotinine.
Hurt, R. Douglas , Offord, Kenneth P., Croghan, Ivana T. , Decker, Paul A. , Morris, Richard A. , Patten, Christi A. , Decker, Paul A. , Hays, J. Taylor

Journal of Studies on Alcohol | March 5, 2015 | Volume: 66 | Issue: 4 | Pages: 506-516

10.15288/jsa.2005.66.506 | PMID 16240558 Get It

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Chen, Minshan , Colombo, M., Roberts, Lewis R. , Schwartz, Myron , Chen, Pei‐Jer , Kudo, Masatoshi , Wagner, Samuel , Orsini, Lucinda, Sherman, Morris , Park, Joong‐Won , Johnson, Philip J. , Roberts, Lewis R , Kudo, Masatoshi

Liver International | March 5, 2015 | Volume: 35 | Issue: 9 | Pages: 2155-2166

10.1111/liv.12818 | PMID 25752327 Get It

Abstract Background & Aims Hepatocellular carcinoma ( HCC ) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large‐scale, longitudinal cohort study undertaken to improve understanding of real‐life management of patients with HCC , from diagnosis to death. Methods Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. Results Forty‐two sites in 14 countries contributed final data for 18 031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China respectively ( P < 0.0001). Conclusions Initial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.
Impact of weight bias and stigma on quality of care and outcomes for patients with obesity
Yeazel, Mark W. , Hellerstedt, Wendy L., Ryn, Michelle van , Phelan, Sean M. , Burgess, Darren J. , Griffin, Joan M. , van Ryn, Michelle

Obesity Reviews | March 5, 2015 | Volume: 16 | Issue: 4 | Pages: 319-326

10.1111/obr.12266 | PMID 25752756 Get It

Summary The objective of this study was to critically review the empirical evidence from all relevant disciplines regarding obesity stigma in order to (i) determine the implications of obesity stigma for healthcare providers and their patients with obesity and (ii) identify strategies to improve care for patients with obesity. We conducted a search of M edline and PsychInfo for all peer‐reviewed papers presenting original empirical data relevant to stigma, bias, discrimination, prejudice and medical care. We then performed a narrative review of the existing empirical evidence regarding the impact of obesity stigma and weight bias for healthcare quality and outcomes. Many healthcare providers hold strong negative attitudes and stereotypes about people with obesity. There is considerable evidence that such attitudes influence person‐perceptions, judgment, interpersonal behaviour and decision‐making. These attitudes may impact the care they provide. Experiences of or expectations for poor treatment may cause stress and avoidance of care, mistrust of doctors and poor adherence among patients with obesity. Stigma can reduce the quality of care for patients with obesity despite the best intentions of healthcare providers to provide high‐quality care. There are several potential intervention strategies that may reduce the impact of obesity stigma on quality of care.
The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer
Song, Shumei , Honjo, Soichiro , Jin, Jiankang , Chang, Shih-Shin, Scott, Ailing W. , Chen, Qiongrong , Kalhor, Neda , Correa, Arlene M. , Hofstetter, Wayne L. , Albarracin, Constance T. , Wu, Tsung‐Teh, Johnson, Randy L. , Hung, Mien‐Chie , Ajani, Jaffer A. , Chang, Shih-Shin, Ajani, Jaffer A

Clinical Cancer Research | March 4, 2015 | Volume: 21 | Issue: 11 | Pages: 2580-2590

10.1158/1078-0432.ccr-14-2191 | PMID 25739674 Get It

Abstract Purpose: Esophageal cancer is an aggressive malignancy and often resistant to therapy. Overexpression of EGFR has been associated with poor prognosis of patients with esophageal cancer. However, clinical trials using EGFR inhibitors have not provided benefit for patients with esophageal cancer. Failure of EGFR inhibition may be due to crosstalk with other oncogenic pathways. Experimental Design: In this study, expression of YAP1 and EGFR were examined in EAC-resistant tumor tissues versus sensitive tissues by IHC. Western blot analysis, immunofluorescence, real-time PCR, promoter analysis, site-directed mutagenesis, and in vitro and in vivo functional assays were performed to elucidate the YAP1-mediated EGFR expression and transcription and the relationship with chemoresistance in esophageal cancer. Results: We demonstrate that Hippo pathway coactivator YAP1 can induce EGFR expression and transcription in multiple cell systems. Both YAP1 and EGFR are overexpressed in resistant esophageal cancer tissues compared with sensitive esophageal cancer tissues. Furthermore, we found that YAP1 increases EGFR expression at the level of transcription requiring an intact TEAD-binding site in the EGFR promoter. Most importantly, exogenous induction of YAP1 induces resistance to 5-fluorouracil and docetaxcel, whereas knockdown of YAP1 sensitizes esophageal cancer cells to these cytotoxics. Verteporfin, a YAP1 inhibitor, effectively inhibits both YAP1 and EGFR expression and sensitizes cells to cytotoxics. Conclusions: Our data provide evidence that YAP1 upregulation of EGFR plays an important role in conferring therapy resistance in esophageal cancer cells. Targeting YAP1-EGFR axis may be more efficacious than targeting EGFR alone in esophageal cancer. Clin Cancer Res; 21(11); 2580–90. ©2015 AACR.
The Impact of Obesity on Perioperative Resource Utilization after Elective Spine Surgery for Degenerative Disease
Planchard, Ryan , Higgins, Dominique , Mallory, Grant W., Puffer, Ross C. , Jacob, Jeffrey T. , Kor, Daryl J. , Planchard, Ryan F, Higgins, Dominique M, Curry, Timothy B. , Clarke, Michelle J.

Global Spine Journal | March 4, 2015 | Volume: 5 | Issue: 4 | Pages: 287-293

10.1055/s-0035-1546819 | PMID 26225277 Get It

Study Design Retrospective case series. Objective To determine the effect of obesity on the resource utilization and cost in 3270 consecutive patients undergoing elective noninstrumented decompressive surgeries for degenerative spine disease at Mayo Clinic Rochester between 2005 and 2012. Methods Groups were assessed for baseline differences (age, gender, and American Society of Anesthesiologists [ASA] classification, procedure type, and number of operative levels). Outcome variables included the transfusion requirements during surgery, the total anesthesia and surgical times, intensive care unit (ICU) admissions, standardized costs, as well as the ICU and hospital length of stay (LOS). Regression analysis was used to evaluate for strength of association between obesity and outcome variables. Results Baseline differences between the groups (nonobese: n = 1,853; obese: n = 1,417) were found with respect to age, ASA class, gender, procedure type, and number of operative levels. After correcting for differences, we found significant associations between obesity and surgical ( p < 0.0001) and anesthesia times ( p < 0.0001) and hospital LOS ( p < 0.0001). Additionally, ICU admission rates ( p = 0.02) and requirement for postoperative ventilation ( p = 0.048) were significantly higher in obese patients. Finally, mean difference in total cost ($1,632, p < 0.0001) was significantly higher for the obese cohort. Conclusion Obesity is associated with increased resource utilization and cost in patients undergoing a noninstrumented decompressive surgery for degenerative spine disease.